ALK and non-small cell lung carcinoma: The second phase III randomized clinical trial, the ALEX trial, was conducted in the Caucasian population with 303 treatment-naïve patients affected by metastatic ALK-positive NSCLC, and compared alectinib with crizotinib in the first-line setting.